Table 3 Characteristics and management of study participants with type 2 diabetes mellitus
Parameter | N = 99 |
|---|---|
Incident T2D | 14 (14%) |
Referred for inpatient diabetes review | 0/14 |
New diagnosis mentioned in discharge letter | 3/14 (21%) |
New diagnosis coded for in medical record | 5/14 (36%) |
Recommended for endocrinology review after discharge | 0/14 |
Known T2D | 85 (85%) |
Referred for inpatient diabetes review | 9/85 (11%) |
Diagnosis mentioned in discharge letter | 82/85 (96%) |
Diagnosis coded for in medical record | 82/85 (96%) |
Recommended for endocrinology review after discharge | 11/85 (13%) |
Management of known T2D | 85 (85%) |
Hyperglycaemia | 23/85 (27%) |
Hypoglycaemia | 6/85 (7%) |
HbA1c > 7% (> 53 mmol/mol) | 43/85 (56%) |
Microvascular complications | 40 (40%) |
Peripheral neuropathy | 7 (7%) |
Retinopathy | 5 (5%) |
Nephropathy (2 on dialysis) | 46 (46%) |
Macrovascular complications | 63 (63%) |
Coronary artery disease | 51 (51%) |
Ischaemic heart disease | 53 (53%) |
Peripheral vascular disease | 6 (6%) |
Carotid stenosis | 4 (4%) |
Stroke/transient ischaemic attack | 12 (12%) |
Diabetes treatment | |
Metformin | 61 (62%) |
Sulphonylurea | 29 (29%) |
Dipeptidyl peptidase-4 inhibitor | 13 (13%) |
Sodium glucose co-transporter 2 inhibitor | 2 (2%) |
Glucagon-like peptide-1 receptor analogue | 0 |
Acarbose | 0 |
Thiazolidinediones | 0 |
None | 26 (26%) |
Insulin | 17 (17%) |
Mean total daily dose (U) | 77.7 ± 53 |
Basal (mean HbA1c 78 mmol/mol, 9.3%) | 4/17 (24%) |
Premixed (mean HbA1c 68 mmol/mol, 8.4%) | 8/17 (47%) |
Basal-bolus (mean HbA1c 56 mmol/mol, 7.3%) | 5/17 (29%) |